A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Inclusion Criteria:

- Must have confirmed solid malignancy that is metastatic, and standard curative
measures or other therapy that may provide clinical benefit do not exist or are no
longer effective.

- For Veliparib monotherapy (must have tumor with defects in DNA repair mechanisms
(BRCA mutation or high grade ovarian cancer or solid tumors for combination therapy.

- If the subject has known brain metastases must have clinically controlled neurologic
symptoms, defined as surgical excision and/or radiation therapy followed by 21 days
of stable neurologic function and no evidence of Central Nervous System (CNS) disease
progression as determined by comparing a computed tomography (CT) scan or magnetic
resonance imaging (MRI) scan performed during screening to a prior scan performed at
least 4 weeks earlier and provided that the subject is asymptomatic, has no evidence
of cavitation or hemorrhage, and does not require corticosteroids (must have
discontinued steroids at least 3 months prior to study drug administration).

- Subject must have adequate bone marrow, renal and hepatic function per local
laboratory reference range.

Exclusion Criteria:

- Subject has a clinically significant and uncontrolled major medical condition(s)
including but not limited to:

- Uncontrolled seizure disorder, including focal or generalized seizure within the last
12 months;

- Uncontrolled nausea/vomiting/diarrhea;

- Active uncontrolled infection;

- Symptomatic congestive heart failure;

- Unstable angina pectoris or cardiac arrhythmia;

- Psychiatric illness/social situation that would limit compliance with study
requirements;

- Any medical condition, which in the opinion of the study investigator, places the
subject at an unacceptably high risk for toxicities.

- Subjects who have hypersensitivity to Carboplatin, Paclitaxel or Cremophor should be
excluded from arm B.

- Subject has received any of the following anti-cancer therapies 21 days prior to the
first dose of study drug or a biologic agent for anti-neoplastic intent within 30
days prior to the first dose of study drug.

- Subject who requires parenteral nutrition, tube feeding or has evidence of a partial
bowel obstruction or perforation within 28 days prior to study drug.

- The subject has had another active malignancy within the past 3 years except for any
cancer in situ that the Principal Investigator considers to be cured.